DP 5511
Alternative Names: DP-5511; n.c.a. 177Lu-FRαTMLatest Information Update: 28 Jul 2024
At a glance
- Originator Isotopen Technologien Munchens
- Class Antineoplastics; Drug conjugates; Radioisotopes; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for phase-I development in Solid-tumours in Germany (Parenteral)
- 25 Jun 2021 Phase-I clinical trials in Solid tumours in Germany (Parenteral) (Isotopien Technologien Munhens pipeline, June 2021)
- 20 May 2020 DP 5511 is available for licensing as of 20 May 2020. https://itm-radiopharma.com/itm-partnering-opportunities